---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-014895"
form_type: "8-K"
ticker: "ZVSA"
cik: "0001859007"
company_name: "ZyVersa Therapeutics, Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T11:13:25.911868+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# ZyVersa shareholders approve up to 3.84M new shares, potentially doubling float

## Summary
- Shareholders approved increasing equity plan share reserve by 100,000 to 382,122 shares.
- Approved issuance of up to 1,637,000 shares upon exercise of November 2024 warrants.
- Approved issuance of up to 2,105,265 shares upon exercise of March 2025 warrants.
- Combined potential dilution (3.84M shares) exceeds current outstanding of 3.62M shares.
- All five proposals including director re-election and auditor ratification passed at June 11 annual meeting.

## SEC filing metadata
- accession: 0001641172-25-014895
- form_type: 8-K
- ticker: ZVSA
- cik: 0001859007
- company_name: ZyVersa Therapeutics, Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1859007/000164117225014895/0001641172-25-014895-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1859007/000164117225014895/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-014895
- JSON: https://secwatch.observer/filing/0001641172-25-014895.json
- Plain text: https://secwatch.observer/filing/0001641172-25-014895.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.